Cargando…
Immediate Infusion Reaction to Intravenous Ustekinumab in Three Crohn’s Disease Patients: A Case Report and Review of the Literature
Recently, ustekinumab has been approved for the treatment of Crohn’s disease and ulcerative colitis. Treatment is started with an intravenous induction dose, followed by a subcutaneous dosage. We present details of three patients with therapy-refractory Crohn’s disease who experienced an immediate i...
Autores principales: | Thomas, Pepijn W A, Ferwerda, Gerben, West, Rachel L, Hoentjen, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805788/ https://www.ncbi.nlm.nih.gov/pubmed/32588044 http://dx.doi.org/10.1093/ecco-jcc/jjaa115 |
Ejemplares similares
-
Long-term effectiveness and safety of ustekinumab in Crohn’s disease: a prospective cohort study
por: Thomas, Pepijn W.A., et al.
Publicado: (2022) -
Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease
por: Kakiuchi, Toshihiko, et al.
Publicado: (2021) -
Late Reaction to Ustekinumab Infusion
por: Morais, Marina Resener, et al.
Publicado: (2013) -
Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
por: Straatmijer, Tessa, et al.
Publicado: (2023) -
Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response
por: Heron, Valerie, et al.
Publicado: (2022)